Dr Rory Chan
Clinical Senior Lecturer Hon Consultant
Respiratory Medicine and Gastroenterology, School of Medicine
Contact
Biography
As a clinical academic specialising in respiratory and general internal medicine, Rory divides his time equally between person-centred airways research and providing inpatient and outpatient emergency care. He is also the year 1 teaching block convenor for respiratory medicine.
Rory maintains strong collaborative partnerships with industry and was recently awarded an unrestricted research grant from Chiesi, AstraZeneca, and GlaxoSmithKline to spearhead the Scottish Airways Research Network, which spans the 11 largest NHS trusts in Scotland. He also serves on the Editorial Board for Asthma in the international journal CHEST.
Research
Key research
- Prospective clinical trial demonstrating novel efficacy of anti-IL5Rα therapy in attenuating mannitol airway hyperresponsiveness in severe eosinophilic asthma. (Chan R et al. J Allergy Clin Immunol. 2023 Mar;151(3):700-705.e10.)
- Health informatics database analyses showed that combining two pulmonary function tests as spirometry and airway oscillometry better identifies higher risk of poor symptom control and more frequent severe exacerbations. (Chan R et al. Eur Respir J. 2022 Oct 13;60(4):2200543.)
- Multidisciplinary team-based approach with thoracic radiologists revealed a close relationship between key asthma outcomes and mediastinal lymph node size (Chan R et al. Am J Respir Crit Care Med. 2024 Feb 1;209(3):331-334.), mucus plugging (Chan R et al. J Allergy Clin Immunol Pract. 2023 Jan;11(1):195-199.e2.) and bronchial wall thickening. (Chan R et al. J Allergy Clin Immunol Pract. 2023 May;11(5):1459-1462.e3.)
- Indirect case-matched comparison of biologics demonstrated greater improvement in small airway dysfunction (Chan R et al. Allergy. 2024 Oct;79(10):2862-2864.) and mannitol airway hyperresponsiveness (Chan R et al. Allergy. 2024 Oct;79(10):2873-2875.) with anti-IL4Rα therapy.